<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02483000</url>
  </required_header>
  <id_info>
    <org_study_id>9189</org_study_id>
    <secondary_id>NCI-2015-00299</secondary_id>
    <secondary_id>9189</secondary_id>
    <secondary_id>P01CA044991</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT02483000</nct_id>
  </id_info>
  <brief_title>Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies</brief_title>
  <official_title>Evaluation of Pretargeted Anti-CD20 Radioimmunotherapy Combined With BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk B-Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and best dose of anti-cluster of
      differentiation (CD)20 radioimmunotherapy (RIT), and to see how well it works when given
      before chemotherapy and stem cell transplant in treating patients with B-cell malignancies
      that have not responded to treatment or have come back after responding to treatment. CD20 is
      a protein found on the cells of a type of cancer cell called B-cells. Anti-CD20 RIT attaches
      radioactive material to a drug that is designed to target CD20, which brings radioactive
      material to the cancer cells to kill the cells. This may kill more tumor cells while causing
      fewer side effects to healthy tissue. Adding anti-CD20 to standard chemotherapy and stem cell
      transplant may be more effective in treating patients with B-cell malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To estimate the maximum tolerated dose (MTD) of 90Y activity that can be delivered via
      pretargeted radioimmunotherapy (PRIT) using B9E9-fusion protein (B9E9-FP), clearing agent
      (CA), and radiolabeled tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-biotin when
      followed by carmustine, etoposide, cytarabine, and melphalan (BEAM) chemotherapy and
      autologous stem cell transplantation.

      SECONDARY OBJECTIVES:

      I. To assess the overall and progression-free survival of the above regimen in such patients.

      II. To evaluate the response rates of the above therapy.

      III. To evaluate the toxicity and tolerability of the above therapy.

      IV. To evaluate the feasibility of delivering sequential high-dose PRIT and chemotherapy.

      TERTIARY OBJECTIVES:

      I. Assess biodistribution and pharmacokinetics of B9E9-FP and radiolabeled DOTA-Biotin.

      II. Assess ability of the clearing agent (CA) to remove excess B9E9-FP from the serum.

      III. Evaluate the impact, if any, of circulating rituximab on biodistributions.

      OUTLINE: This is a phase I, dose-escalation study of yttrium Y 90 DOTA-biotin followed by a
      phase II study.

      B9E9-FP INFUSION: Patients receive B9E9-fusion protein intravenously (IV) over a minimum of 2
      hours on day -17.

      CLEARING AGENT INFUSION: Patients receive clearing agent IV over a minimum of 30 minutes on
      day -15.

      RADIOBIOTIN INFUSION: Patients receive indium In 111-DOTA-biotin IV and yttrium Y 90
      DOTA-biotin IV over 2-5 minutes on day -14.

      BEAM CHEMOTHERAPY: Patients receive BEAM chemotherapy comprising carmustine IV over 3 hours
      on day -7; etoposide IV over 2 hours twice daily (BID) and cytarabine IV over 4 hours BID on
      days -6 to -3; and melphalan IV over 30 minutes on day -2.

      STEM CELL INFUSION: Patients undergo autologous peripheral blood stem cell transplant (PBSCT)
      on day 0 per standard of care.

      After completion of study treatment, patients are followed up at 1, 3, 6, and 12 months, and
      then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">March 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of yttrium Y 90 DOTA-biotin defined as the dose that is associated with a true dose limiting toxicity (DLT) rate of 25%, where a DLT is defined as a therapy-related grade III or IV Bearman (transplant) toxicity</measure>
    <time_frame>Up to 30 days after transplant</time_frame>
    <description>Following the completed observation of the final patient, a two-parameter logistic model will be fit to the data, thereby generating a dose-toxicity curve based on the observed DLT rate at the various dose levels visited. Based on this fitted model, the MTD is estimated to be the dose that is associated with a DLT rate of 25%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dosimetry of yttrium Y 90 DOTA-biotin</measure>
    <time_frame>Up to 7 days after infusion</time_frame>
    <description>Assessed using OLINDA dosimetry software. The estimated dose to normal organs and tumor sites will be described based on the tumor to normal organ ratios derived from dosimetry estimates coupled with the absorbed dose to normal organs based on the administered activity of yttrium Y 90 DOTA-biotin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of toxicity, defined according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</measure>
    <time_frame>Up to 30 days after transplant</time_frame>
    <description>Descriptive statistics on the number and percent toxicities will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Descriptive statistics on the responses will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Overall survival will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>1 year from autologous stem cell transplant</time_frame>
    <description>If the true 1-year PFS rate using the proposed approach is 54%, then 24 patients will provide 80% power to detect a statistically significant increased rate of PFS from the fixed rate of 30%, based on a one-sample chi-square test with one-sided significance level of 5%.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Burkitt Lymphoma</condition>
  <condition>CD20-Positive Neoplastic Cells Present</condition>
  <condition>Diffuse Large B-Cell Lymphoma</condition>
  <condition>Indolent Non-Hodgkin Lymphoma</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Recurrent B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Refractory Mature B-Cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (PRIT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B9E9-FP INFUSION: Patients receive B9E9-fusion protein IV over a minimum of 2 hours on day -17.
CLEARING AGENT INFUSION: Patients receive clearing agent IV over a minimum of 30 minutes on day -15.
RADIOBIOTIN INFUSION: Patients receive indium In 111-DOTA-biotin IV and yttrium Y 90 DOTA-biotin IV over 2-5 minutes on day -14.
BEAM CHEMOTHERAPY: Patients receive BEAM chemotherapy comprising carmustine IV over 3 hours on day -7; etoposide IV over 2 hours BID and cytarabine IV over 4 hours BID on days -6 to -3; and melphalan IV over 30 minutes on day -2.
STEM CELL INFUSION: Patients undergo autologous PBSCT on day 0 per standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (PRIT)</arm_group_label>
    <other_name>Anti-CD20 B9E9 scFv-SA Fusion Protein</other_name>
    <other_name>Anti-CD20 B9E9-SA Fusion Protein</other_name>
    <other_name>B9E9 scFvSA Fusion Protein</other_name>
    <other_name>Recombinant Anti-CD20 B9E9 scFvSA Fusion Protein</other_name>
    <other_name>scFv B9E9-streptavidin Fusion Protein</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous PBSCT</description>
    <arm_group_label>Treatment (PRIT)</arm_group_label>
    <other_name>Autologous Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (PRIT)</arm_group_label>
    <other_name>BCNU</other_name>
    <other_name>Becenum</other_name>
    <other_name>Becenun</other_name>
    <other_name>BiCNU</other_name>
    <other_name>Bis(chloroethyl) Nitrosourea</other_name>
    <other_name>Bis-Chloronitrosourea</other_name>
    <other_name>Carmubris</other_name>
    <other_name>Carmustin</other_name>
    <other_name>Carmustinum</other_name>
    <other_name>FDA 0345</other_name>
    <other_name>Gliadel</other_name>
    <other_name>N,N'-Bis(2-chloroethyl)-N-nitrosourea</other_name>
    <other_name>Nitrourean</other_name>
    <other_name>Nitrumon</other_name>
    <other_name>SK 27702</other_name>
    <other_name>SRI 1720</other_name>
    <other_name>WR-139021</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clearing Agent</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (PRIT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (PRIT)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-Cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (PRIT)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Indium In 111-DOTA-Biotin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (PRIT)</arm_group_label>
    <other_name>In 111-DOTA-Biotin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (PRIT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (PRIT)</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine Nitrogen Mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous PBSCT</description>
    <arm_group_label>Treatment (PRIT)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (PRIT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Yttrium Y 90-DOTA-Biotin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (PRIT)</arm_group_label>
    <other_name>90Y-DOTA-Biotin</other_name>
    <other_name>yttrium Y 90 DOTA-biotin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a histologically confirmed diagnosis of lymphoma expressing the
             CD20 antigen and generally must have failed at least one prior standard systemic
             therapy; the exception will be mantle cell lymphoma (MCL) patients, who may be
             enrolled while in first complete remission (CR) as well as other select high-risk
             lymphomas (e.g., Burkitt?s, double hit diffuse large B-cell lymphoma [DLBCL],
             transformed indolent B-cell non-Hodgkin lymphoma [B-NHL], etc.) in accordance with
             current transplant standard of care for these patients

          -  Creatinine (Cr) &lt; 2.0

          -  Bilirubin &lt; 1.5 mg/dL, with the exception of patients thought to have Gilbert?s
             syndrome, who may have a total bilirubin above 1.5 mg/dL

          -  All patients eligible for therapeutic study must have (&gt;= 2 x 10^6 CD34/kg) autologous
             hematopoietic stem cells harvested and cryopreserved

          -  Patients must have an expected survival of &gt; 60 days and must be free of major
             infection

          -  Patients of childbearing potential must agree to abstinence or the use of effective
             contraception

          -  DONOR SELECTION: Not applicable; this protocol employs autologous transplantation,
             utilizing the patient?s own hematopoietic stem cells obtained from either the
             peripheral blood or bone marrow

        Exclusion Criteria:

          -  Systemic anti-lymphoma therapy given in the previous 30 days before the scheduled 90Y
             therapy dose

          -  Inability to understand or give an informed consent

          -  Prior radiation &gt; 20 Gy to any critical normal organ (e.g., lung, liver, spinal cord,
             both kidneys) within 1 year of the treatment date

          -  Active central nervous system lymphoma

          -  Other serious medical conditions considered to represent contraindications to bone
             marrow transplant (BMT) (e.g., abnormally decreased cardiac ejection fraction,
             diffusion capacity of the lung for carbon monoxide [DLCO] &lt; 50% predicted, patient on
             supplemental oxygen, acquired immune deficiency syndrome [AIDS], etc.)

          -  Pregnancy or breast feeding

          -  Prior bone marrow or stem cell transplant

          -  Southwest Oncology Group (SWOG) performance status &gt;= 2.0

          -  Known sensitivity to kanamycin and other aminoglycosides; patients with known
             hypersensitivity to kanamycin or any other aminoglycoside antibiotic will be excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajay Gopal</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajay K. Gopal</last_name>
      <phone>206-288-2037</phone>
      <email>agopal@u.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Ajay K. Gopal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2015</study_first_submitted>
  <study_first_submitted_qc>June 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2015</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Biotin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

